Move fast and break things doesn’t work when the thing you might break is a pregnancy scan. That’s the reality TechCrunch AI dug into with Robhy Bustami, co-founder and CEO of BioticsAI, on the Build Mode podcast. His company just landed FDA approval in January for an AI copilot that helps sonographers detect fetal abnormalities, and the path he describes looks nothing like the typical AI startup playbook.
What stands out here is how early the regulatory mindset kicked in. Most AI founders ship first, ask questions later. BioticsAI baked clinical validation, regulatory strategy, and product development into one workflow from day one, according to TechCrunch AI. They worked alongside clinicians, ran structured clinical studies, and engaged the FDA through pre-submission meetings before they ever filed. The result: a working prototype built for under $100,000, a Startup Battlefield win in 2023, and now clearance to deploy in hospitals.
Why this matters now
Healthcare AI is having a moment, but the gap between demo and deployment is a graveyard. Plenty of impressive models never make it into a clinical workflow because founders underestimate what the FDA actually requires. BioticsAI’s story is a counter-example worth studying because it proves the process isn’t a black box if you treat regulators as collaborators, not gatekeepers.
The broader trend: capital is flowing into medical AI faster than ever, but the winners aren’t the teams with the flashiest models. They’re the ones who understand that rigor compounds. Every clinical study, every dataset, every pre-sub meeting becomes a moat. Competitors who skip those steps end up rebuilding from scratch when the FDA pushes back.
The investor question nobody wants to answer
Bustami flagged the question that haunts every healthcare AI deal: what if the FDA says no? Long timelines create a second problem on top of that, which is keeping engineers and clinicians motivated when the biggest milestone is years out. His answer was cultural. Make sure everyone, even outside their technical scope, sees the wins as they happen. Clinical study results. New hospital partnerships. R&D progress.
That’s a leadership lesson that translates beyond healthcare. Any AI startup chasing a hard, slow goal needs the same discipline.
Practical takeaways
For founders building in regulated AI verticals, the BioticsAI playbook offers a few moves worth copying:
- Engage regulators early. Pre-submission meetings clarify study design and expectations. Skip them and you’re guessing.
- Bundle the workstreams. Treat regulatory, clinical, and product as one integrated process, not three separate tracks that meet at the end.
- Recruit clinicians as co-builders. Their input shapes the dataset, the validation strategy, and the credibility of your submission.
- Build a milestone cadence. When the big win is years away, manufacture smaller wins so the team stays sharp.
- Capital efficiency wins credibility. A $100,000 prototype that works beats a $10 million prototype that hasn’t been clinically validated.
For businesses evaluating healthcare AI vendors, the signal flips. Ask how early the team engaged the FDA. Ask how their dataset was assembled. Ask who their clinical partners are. Vendors who can answer crisply are the ones likely to still be standing in three years.
What comes next
BioticsAI is moving into deployment now, rolling into hospitals and planning expansion beyond obstetrics into broader reproductive health. That’s the second hard part of healthcare AI: clearance gets you to the starting line, but adoption inside hospital workflows is its own slog. Procurement cycles, IT integration, clinician training, reimbursement codes. Each one is a battle.
Still, the FDA stamp changes the conversation. It moves the company from “interesting startup” to “deployable medical device,” and the gap between those two categories is where most healthcare AI dies.
Founders chasing this path should expect a long road. The reward, as Bustami frames it, isn’t just a successful exit. It’s tech that actually changes how care gets delivered. Read the full conversation on TechCrunch AI’s Build Mode.